Potential treatments for COVID-19 vaccinated people

vaccine vial and needle

This page is updated often so please bookmark it and check back.

One of the significant problems with the COVID-19 "vaccines" (by definition they are not vaccines) is the spike protein which is causing a plethora of diseases in many vaccinated people including blood clots, strokes, heart attacks and death, even in very young, healthy people. It appears those who have been injected with these toxic gene therapy cocktails may be shedding the spike protein, thus affecting the unvaccinated as well.

Fortunately some doctors, scientists and others are offering potential solutions. Several treatments for combating the damage done by the spike protein mirror those which are used to combat the alleged virus, SARS-CoV-2.

Please do your own research before subjecting yourself to any treatment.

Resolving "Long-Haul COVID" and Vaccine Toxicity: Neutralizing the Spike Protein

Commentary by Thomas E. Levy, MD, JD

(OMNS June 21, 2021) Although the mainstream media outlets might have you believe otherwise, the vaccines that continue to be administered for the COVID pandemic are emerging as very substantial sources of morbidity and mortality themselves. While the degree to which these negative outcomes of the COVID vaccines can be debated, there is no question that enough disease and death have already occurred to warrant cessation of the administration of these vaccines until additional, completely scientifically-based research can examine the balance between its now clear-cut side effects versus its potential (and still not yet clearly proven) ability to prevent new COVID infections.

more...

Worse Than Covid? Spike Protein Spreads Like Fire

By Dr. Betty Martini, D.Hum
6-15-21

While all of this is highly problematic, there is help. As noted by Mikovits, remedies to the maladies that might develop post-vaccination include:

Hydroxychloroquine and ivermectin treatments. Ivermectin appears particularly promising as it actually binds to the spike protein. Please listen to the interview that Brett Weinstein did with Dr. Pierre Kory,19 one of Dr. Paul Marik's collaborators

Low-dose antiretroviral therapy to reeducate your immune system

Low-dose interferons such as Paximune, developed by interferon researcher Dr. Joe Cummins, to stimulate your immune system

Peptide T (an HIV entry inhibitor derived from the HIV envelope protein gp120; it blocks binding and infection of viruses that use the CCR5 receptor to infect cells)

Cannabis, to strengthen Type I interferon pathways

Dimethylglycine or betaine (trimethylglycine) to enhance methylation, thereby suppressing latent viruses

Silymarin or milk thistle to help cleanse your liver

more...

(PDF) Common dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro (archived copy)

On 11th March 2020, coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, was declared as a global pandemic by the World Health Organization (WHO). To date, there are rapidly spreading new “variants of concern” of SARS-CoV-2, the United Kingdom (B.1.1.7), the South African (B.1.351) or Brasilian (P.1) variant. All of them contain multiple mutations in the ACE2 receptor recognition site of the spike protein, compared to the original Wuhan sequence, which is of great concern, because of their potential for immune escape. Here we report on the efficacy of common dandelion ( Taraxacum officinale ) to block protein-protein interaction of spike S1 to the human ACE2 cell surface receptor. This could be shown for the original spike D614, but also for its mutant forms (D614G, N501Y, and mix of K417N, E484K, N501Y) in human HEK293-hACE2 kidney and A549-hACE2-TMPRSS2 lung cells. High molecular weight compounds in the water-based extract account for this effect. Infection of the lung cells using SARS-CoV-2 spike pseudotyped lentivirus particles was efficiently prevented by the extract and so was virus-triggered pro-inflammatory interleukin 6 secretion.

more...

Accompanying articles:

Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

Objective: No drug is yet approved to treat the core symptoms of autism spectrum disorder (ASD). Low-dose suramin was effective in the maternal immune activation and Fragile X mouse models of ASD. The Suramin Autism Treatment-1 (SAT-1) trial was a double-blind, placebo-controlled, translational pilot study to examine the safety and activity of low-dose suramin in children with ASD.

Accompanying articles:

Spike Detox and General Health

Some REAL health professionals have claimed the body may be able to rid itself of the spike proteins or at least alleviate the deadly damage they cause by using certain products.

more...

Breakthrough: This fermented Japanese superfood can inhibit SARS-CoV-2 infections, researchers find – NaturalNews.com

Natto extract degrades key region of SARS-CoV-2 spike protein

Natto is a traditional Japanese dish made by fermenting soybeans with Bacillus subtilis, a bacterium typically found in soil and vegetation. It is a staple in the diets of people who are least likely to die from stroke and cardiovascular disease, which is why it is thought to contribute to longer, healthier lives across Japan.

For their study, the researchers examined whether natto can impair infection by SARS-CoV-2 and bovine herpesvirus 1 (BHV-1), a major pathogen of cattle that causes severe respiratory infection.

The researchers prepared two natto extracts. One of the extracts was heated at 100 degrees Celsius for 10 minutes. They applied the extracts to sets of lab-cultured cells from cattle and humans. One set of human cells was infected with SARS-CoV-2 and one set of cattle cells was infected with BHV-1.

The results showed that SARS-CoV-2 and BHV-1 lost the ability to infect cells when treated with the unheated natto extract. However, treating the viruses with the heated extract had no effect.

more...

Leave a Reply

Your email address will not be published. Required fields are marked *